Abstract
Many genetic polymorphisms in metabolism enzymes are important for the risk of cancer as shown in a large number of case-control studies. Cytochrome P-450 (CYP) 1A1 polymorphism is a widely mentioned for importance of its genetic polymorphisms in risk assessment. However, the reports on the correlation between polymorphism and risk are inconsistent. To study the functional aberration in the human wild and mutate types of CYP1A1 is hard. Here, the author used a new gene ontology technology to predict the molecular function of human CYP1A1. Here, it can be seen that there is no functional difference between wild and mutate types of CYP1A1. Therefore, there should be no difference in effect of wild and mutate types of CYP1A1. This can support the null effect of this polymorphism in clinical findings of the population. This polymorphism might not be an important tool for risk assessment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Stochastic Environmental Research and Risk Assessment
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
